trending Market Intelligence /marketintelligence/en/news-insights/trending/EU27fWWx7RhC6R62HcuwjA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

AbbVie files for US FDA approval of elagolix in uterine fibroids

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

AbbVie files for US FDA approval of elagolix in uterine fibroids

AbbVie Inc. has filed for U.S. Food and Drug Administration approval of its women's health drug elagolix to treat heavy menstrual bleeding in women with uterine fibroids.

Elagolix, also known as Orilissa, is an oral gonadotropin-releasing hormone, or GnRH, antagonist developed by North Chicago, Ill.-based AbbVie. Uterine fibroids are noncancerous muscle tissue tumors that develop in a woman's uterus. As many as 70% of white women and 80% of black women will be affected by fibroids by age 50. While fibroids can be asymptomatic, some women experience heavy menstrual bleeding outside of their usual menstruation and anemia.

The drug was submitted to the U.S. regulator based on data from a phase 3 clinical trial program that featured 800 premenopausal women with uterine fibroids. Heavy bleeding was reduced in the women taking elagolix.

AbbVie is racing to market with elagolix against a number of similar products under development. Myovant Sciences Ltd. in July announced that the company's similar treatment, relugolix, reduced heavy menstrual bleeding in women with a single-pill treatment regimen. ObsEva SA also has a GnRH antagonist called linzagolix underway for uterine fibroids.

Elagolix is already approved to treat endometriosis and is being studied in polycystic ovary syndrome, which causes infrequent or prolonged menstrual periods.

SNL Image